Mayo Clinic Laboratories in the UnitedHealthcare Preferred Lab Network - Insights
Mayo Clinic Laboratories is pleased to announce it has been selected as a UnitedHealthcare Preferred Lab Network (PLN) care provider. Under the agreement, effective July 1, 2019, UnitedHealthcare members have in-network access to Mayo...
Forging ahead in the MLS Program - Insights
Elizabeth Atneosen, a student in the Mayo Clinic Medical Laboratory Science program, talks about the rewards of being in the program.
Looking Back on Clinical Chemistry 1 - Insights
Kylie Reising, a student in the Mayo Clinic Medical Laboratory Science program, takes a look back on her Clinical Chemistry 1 course.
William Morice, II, M.D., Ph.D., Featured in The Athletic - Insights
Dr. Morice was recently featured in The Athletic regarding sports teams and how to safely and efficiently bring them back.
Protimes, Clotting, and Fibrin-Oh My: A Reflection on Hemostasis - Insights
Reilly Hannon, a student in the Mayo Clinic Medical Laboratory Science program, reflects on her course in hemostasis.
Innovative Alzheimer's disease diagnostic tool unveiled - Insights
Mayo Clinic Laboratories has marked a significant advancement in the fight against Alzheimer's disease with the introduction of an innovative diagnostic test. This noninvasive blood test accurately detects the p-Tau217 biomarker, indicative...
MLS Clinical Rotations Spotlight: Hematology - Insights
Alex Harker, a student in Mayo Clinic’s Medical Laboratory Science (MLS) class of 2017, discusses his MLS clinical rotation in the Hematology Laboratory.
Bobbi Pritt, M.D., and Matthew Binnicker, Ph.D., offered insight on testing accuracy, as well as circumstances that could affect a test's reliability.
Mayo Clinic Laboratory and pathology research roundup: November 2 - Insights
This week’s research roundup features: Phase II randomized trial of transoral surgery and low-dose intensity Modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: An ECOG-ACRIN cancer research group trial...
Patients with Blood Cancer Precursor at Risk of Developing Cancer Even after 30 Years - Insights
Patients with monoclonal gammopathy of undetermined significance are at risk of progressing to multiple myeloma or a related cancer─even after 30 years of stability, according to findings of a study by Mayo Clinic researchers published in...